» Articles » PMID: 37623261

Probiotics and Fecal Transplant: An Intervention in Delaying Chronic Kidney Disease Progression?

Overview
Journal Clin Pract
Publisher MDPI
Specialty General Medicine
Date 2023 Aug 25
PMID 37623261
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease (CKD) is a global health challenge affecting nearly 700 million people worldwide. In the United States alone, the Medicare costs for CKD management has reached nearly USD 80 billion per year. While reversing CKD may be possible in the future, current strategies aim to slow its progression. For the most part, current management strategies have focused on employing Renin Angiotensin Aldosterone (RAS) inhibitors and optimizing blood pressure and diabetes mellitus control. Emerging data are showing that a disruption of the gut-kidney axis has a significant impact on delaying CKD progression. Recent investigations have documented promising results in using microbiota-based interventions to better manage CKD. This review will summarize the current evidence and explore future possibilities on the use of probiotics, prebiotics, synbiotics, and fecal microbial transplant to reduce CKD progression.

Citing Articles

Gut bacteria: an etiological agent in human pathological conditions.

Islam M, Mahbub N, Hong S, Chung H Front Cell Infect Microbiol. 2024; 14:1291148.

PMID: 39439902 PMC: 11493637. DOI: 10.3389/fcimb.2024.1291148.


COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens.

Raj S, Bruce A, Anbalagan M, Srinivasan H, Chinnappan S, Rajagopal M Front Cell Infect Microbiol. 2024; 14:1384939.

PMID: 38863829 PMC: 11165100. DOI: 10.3389/fcimb.2024.1384939.


Exploring the Impact of Optimized Probiotic Supplementation Techniques on Diabetic Nephropathy: Mechanisms and Therapeutic Potential.

Ghosh A, Muley A, Ainapure A, Deshmane A, Mahajan A Cureus. 2024; 16(2):e55149.

PMID: 38558739 PMC: 10979819. DOI: 10.7759/cureus.55149.

References
1.
Wang I, Wu Y, Yang Y, Ting I, Lin C, Yen T . The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes. 2015; 6(4):423-30. DOI: 10.3920/BM2014.0088. View

2.
Hernandez-Chirlaque C, Aranda C, Ocon B, Capitan-Canadas F, Ortega-Gonzalez M, Carrero J . Germ-free and Antibiotic-treated Mice are Highly Susceptible to Epithelial Injury in DSS Colitis. J Crohns Colitis. 2016; 10(11):1324-1335. DOI: 10.1093/ecco-jcc/jjw096. View

3.
Zheng H, Guo J, Wang Q, Wang L, Wang Y, Zhang F . Probiotics, prebiotics, and synbiotics for the improvement of metabolic profiles in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020; 61(4):577-598. DOI: 10.1080/10408398.2020.1740645. View

4.
Fijan S . Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014; 11(5):4745-67. PMC: 4053917. DOI: 10.3390/ijerph110504745. View

5.
Veerappan G, Betteridge J, Young P . Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2012; 14(4):324-33. DOI: 10.1007/s11894-012-0265-5. View